News | Computed Tomography (CT) | December 01, 2020

United Imaging Caps Year of Expansion with Major Product Launches at RSNA

The company spotlights computed tomography and artificial intelligence technology, as well as its recently opened U.S. factory and showroom

The company spotlights computed tomography and artificial intelligence technology, as well as its recently opened U.S. factory and showroom

December 1, 2020 — United Imaging, a platinum sponsor at RSNA's virtual conference, announced the uCT ATLAS, a 510k pending ultra-wide bore computed tomography system with innovative AI technology.

The announcement rounds out a year in which United Imaging reached over 10,500 installations worldwide, including first installations in a number of countries such as Ukraine, Ghana, Kenya, Thailand, Argentina and New Zealand.

In the U.S., the company opened new headquarters facilities in Houston, Texas with a state-of-the-art factory and showroom built for future expansion in the region.

United Imaging President Al Zhang, M.D., said: "It was a challenging year for the industry, but we feel more strongly than ever that the protection of people's lives and health requires technical innovation. Since the outbreak of COVID-19, United Imaging has been working hand-in-hand with people all over the world, offering the latest solutions designed for pandemic control and delivering them to more than 20 countries and regions globally. Meanwhile, we still devote ourselves to developing world-leading equipment and technologies. We want to continue to live up to our mission of equal access to healthcare for all through innovation."

The most recent star of the company's product portfolio is the uCT ATLAS, announced on the opening day of RSNA. The uCT ATLAS, which is 510(K) pending, is a 640-slice CT system with a 16 cm detector, 0.25 second rotation speed, and a low dose 60 kVp capability. The uCT ATLAS enables the ability to image more patients comfortably with its large 82-cm bore and a 700 lbs. table weight capacity. The uCT ATLAS helps expand clinical flexibility with features that support better workflow for patients in the emergency department, a one-rotation cardiac capability and even total stroke imaging, for example. It also is a highly intelligent machine, featuring a uAI Vision integrated 3D camera and an AI-empowered workflow that routinely makes examinations easier and lowers patient radiation doses.

"That's why we say it has Attainable Intelligence," commented David Bradley, who heads the Computed Tomography and X-ray business in the U.S. "It really is a powerhouse of a machine, and the most intelligent we've launched thus far."

Speaking of intelligence, as a sponsor at RSNA of the AI Theater, United Imaging Intelligence will showcase the next-generation AI technologies behind United Imaging's newly FDA cleared Image Reconstruction products: uAI ACS (AI-assisted Compressed Sensing), uAI HYPER DLR deep learning PET image reconstruction algorithm, and CT uAI DELTA low-dose imaging technology.

According to the U.S. CEO of United Imaging Healthcare Solutions, Jeffrey M. Bundy, Ph.D., the uCT ATLAS and the innovations in artificial intelligence join an array of firsts, from this year's debut of the ultra-wide 75 cm 3T uMR OMEGA to the continued growth of its digital mobile PET/CTs. "We also announced a number of partnerships and collaborations, and celebrated new customer relationships," he said. "We have all the appropriate protocols in place to welcome customers to our new showroom and factory in person. However, we've also been doing very successful virtual visits and gotten fantastic feedback on those. We've always said that we were built for the modern world, and that's even more true and more important these days than ever before."

United Imaging is hosting virtual U.S. headquarters tours on three consecutive days from Tuesday Dec. 1 through Thursday Dec. 3, at 12 noon (Central Time) each day, for registered RSNA participants. To attend, simply log into the Virtual Meeting Room within the United Imaging booth at that time.

The uCT ATLAS will be launched within RSNA's virtual platform, along with the uMR OMEGA, Sunday, November 29 at 5:00pm (Central Time) in a session called Access for All: New Technologies from United Imaging.

On Monday, November 30 at 5 pm (Central Time) the company had a second presentation called Beyond the Status Quo: Buying and Owning Medical Technology Differently, in which they will cover offers that give healthcare providers more flexibility with their investment and more long-term value.

"We have representatives from our whole company globally engaged in RSNA," added Zhang, "and while we will miss seeing everyone in person, I think our team's passion will be very clear and very strong, just as it always is."

For more information: www.unitedimaging.com

Related Content

Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors | February 25, 2021
February 25, 2021 — Guerbet announced the launch of ...
Advanced technologies and applications such as point-of-care, pediatrics, dry-magnets, compact MRI and fusion imaging are driving global market
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Frost & Sullivan's recent analysis, Technological Advancements and Emerging Applications in t
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
Detroit-based magnetic resonance imaging (MRI) technology company SpinTech, Inc. has acquired medical-imaging research and technology developer Magnetic Resonance Innovations, Inc. (MR Innovations).
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Detroit-based magnetic resonance...
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

Image courtesy of UCLA Health

News | PET-CT | February 23, 2021
February 23, 2021 — A...
icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio
News | Artificial Intelligence | February 23, 2021
February 23, 2021 — icometrix, world leader in imaging...
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne